Search Results
Treating high risk CLL with BTK inhibitors
Identifying patients with CLL at a high risk of developing cardiotoxicity with BTK inhibitors
Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax
Embracing Newer Therapies in High-Risk CLL
Defining high-risk CLL: known and emerging mutations
The Winning Way With BTK Inhibitors in CLL
BTK Inhibitors in CLL: Treatment Selection
The definition of high-risk CLL
Chronic lymphocytic leukemia (CLL): Advances in research & treatment: 2024 Leukemia Conference, LLSC
Dr. Pinilla-Ibarz on Ibrutinib's Efficacy in Treating High-Risk Patients With CLL
Treating CLL after venetoclax or BTK inhibitors
New Standards for CLL Care With BTK Inhibitors
